Yazar "Meyer, Tim" seçeneğine göre listele
Listeleniyor 1 - 3 / 3
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase III CELESTIAL trial.(Amer Soc Clinical Oncology, 2019) Abou-Alfa, Ghassan K.; Meyer, Tim; Cheng, Ann-Lii; Cicin, Irfan; Bolondi, Luigi; Klumpen, Heinz Josef; Chan, Stephen Lam[Abstract Not Available]Öğe Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial.(Amer Soc Clinical Oncology, 2018) Abou-Alfa, Ghassan K.; Meyer, Tim; Cheng, Ann-Lii; El-Khoueiry, Anthony; Rimassa, Lorenza; Ryoo, Baek-Yeol; Cicin, Irfan[Abstract Not Available]Öğe Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.(Lippincott Williams & Wilkins, 2018) Abou-Alfa, Ghassan K.; Meyer, Tim; Cheng, Ann-Lii; El-Khoueiry, Anthony B.; Rimassa, Lorenza; Ryoo, Baek-Yeol; Cicin, Irfan[Abstract Not Available]
